Pricing Log in Create free account

Genelux Corporation (GNLX) vs Rallybio Corporation (RLYB)

Genelux Corporation and Rallybio Corporation are both Biotechnology companies. Genelux Corporation and Rallybio Corporation are of similar size ($88.7M and $85.6M). Genelux Corporation has negative trailing earnings, so its P/E is not meaningful; Rallybio Corporation trades at 3.3×. Across the 12 metrics below, Rallybio Corporation leads on 9 and Genelux Corporation on 3.

Valuation

Metric GNLX RLYB Biotechnology median
P/E n/m 3.35 10.26
P/S 7.24 104.84 9.18
P/B 5.05 0.97 2.05
Price to free cash flow n/m 2.91 24.81
EV/EBITDA n/m 0.03 0.65
EV/Sales 6.33 (0.86) 8.98
Earnings yield (47.51%) 29.87% (34.89%)
Free cash flow yield (35.25%) 34.41% (24.52%)

Profitability

Metric GNLX RLYB Biotechnology median
Gross margin (3.42%) 100.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (177.93%) 34.52% (50.12%)
Return on assets (121.80%) 32.85% (45.60%)
Return on invested capital 0.00% (944.36%) 0.00%

Growth

Metric GNLX RLYB Biotechnology median
Revenue growth (TTM) — 1.18% 6.26%
EPS growth (last fiscal year) 9.47% 85.06% 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GNLX RLYB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.39 28.87 4.89
Net debt to EBITDA 0.44 1.63 1.01

Dividend

Metric GNLX RLYB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric GNLX RLYB Biotechnology median
Market cap 88.68m 85.61m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack